Serum lipid and lipoprotein concentrations treated and non-treated with statins in post-renal transplant patient (Tx)
DOI:
https://doi.org/10.12923/Keywords:
lipids, lipoproteins, statins, post-renal transplant patientsAbstract
Cardiovascular diseases (CVDs), including acute myocardial infarction, cardiac arrhytmias, heart failure and stroke have become the leading cause of mortality in renal transplant recipients, accounting for over 50% of deaths in these patients. The studies were performed in 20 renal transplant patients (Tx) (male and female) at the age between 21–60 years and the reference group. Tx patients were without an active inflammatory disease, liver disease, malignancy, or diabetes mellitus, and they were not smokers. Seventeen patients had hypertension. The causes of renal insufficiency in the post-renal transplant (Tx) patients were: 11 glomerulonephritis, 5 interstitial nephritis, 2 polycystic disease, 2 hypertensive nephrosclerosis. The post-renal transplant patients received cyclosporine A (CsA) + prednisone (n=13), tacrolimus + prednisone (n=7) and atrovastatine or simvastatine (n=10). They received a low dose of statins. Tx patients (n=20) were divided into 2 groups: Tx patients with (n=10) and without statins therapy (n=10). The present study examined clinical and routine laboratory parameters and lipids, lipoproteins and lipid and lipoproteins ratios in Tx patients treated and non-treated with statins. Lipids, lipoproteins, routine laboratory parameters were obtained in the serum after 14-hour overnight fasting. Routine laboratory parameters (the level of urea, uric acid, creatinine, total protein, albumin) and lipids and lipoproteins (apoA, apoB) were determined on Hitachi 902 analyzer, and hemoglobin using ADVIA analyser, Bayer. LDL-cholesterol (LDL-C) was calculated according to the Friedewald formula. Non-HDL-cholesterol (non-HDL-C) was calculated as total cholesterol (TC) minus HDL-C. The obtained results in Tx patients with statins therapy shows worse clinical and laboratory parameters. The results indicated that Tx patients with statins therapy had a significantly higher concentration of TG, non-HDL-C and TC/HDL-C, TG/HDL-C ratios, and a lower concentration of HDL-C, and apoAI/apoB, HDL-C/apoAI ratios than Tx patients without statins therapy. However, the concentrations TC, LDL-C and apoB were simile in both studied group. Moreover, in both concentrations of TG, non-HDL-C and TC/HDL-C, LDL-C/HDL-C, TG/HDL-C ratios were significantly increased, but HDL-C level and apoAI/apoB, HDL-C/apoAI ratios were decreased in comparison to the reference group. A variety of immunosuppressive therapies in Tx patients are seen to be one of the main factors that influence post-renal transplant abnormal lipid and lipoprotein profiles. The statins therapy demonstrate a favourable effect on the concentration of total cholesterol and LDL-cholesterol but a minor role in triglyceride and HDL-cholesterol levels. Statins can prevent progression of atherosclerosis and chronic allograft failure in Tx patients. However, future studies are required.
References
1. Fellstrom B., Holdaas H., Jardine A.: Cardiovascular Disease in Renal Transplantation: Management by Statins. Transplant. Rev., 18, 122, 2004.
2. Fellstrom B., Jardine A.G., Soveri I. et al: Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am. J. Tranplant., 5, 1986, 2005.
3. Friedewald W.T., Levy R.I., Frierickson D.S.: Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin. Chem., 18, 499, 1972.
4. Harngi M., Mirdamadi H., Seres I. et al: Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase. Transplant. Res., 153, 190, 2009.
5. Hariparshad S.P., Madala N.D., Assounga A.G.H.: Statin therapy ameliorates renal allograft function. Transplant. Proc., 41, 4178, 2009.
6. Jones P.H., Hunninghake D.B., Ferdinand K.C., et al.: Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin. Ther., 26, 1388, 2004.
7. Kasiske B.L., Cakkera H.A., Roel J.: Explained and unexplained ischemic heart disease risk after renal transplantation. J. Am. Soc. Nephrol., 11, 1735, 2000.
8. Kawano M., Nagasaka S. et al.: Pitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. J. Atheroscler. Thromb., 15, 41, 2008.
9. Kimak E., Hałabiś M.: Serum hypertriglyceridemia as an important risk factor of chronic allograft failure in post-renal transplant patients. Annales UMCS, Sect. DDD, 22, 115, 2009.
10. Kimak E., Książek A. et al.: Disturbed lipids, lipoproteins and triglyceride rich-lipoproteins as well as fasting and nonfasting non-high–density lipoprotein cholesterol in post-renal transplant patients. Ren. Fail., 29, 705, 2007.
11. Kimak E., Solski J. et al: Serum lipid, leptin, parameters of oxidative stress and PON-1 activity in post-renal transplant patients. Annales UMCS. Sect. DDD, 21, 355, 2008.
12. Kimak E., Hałabiś M., Baranowicz-Gąszczyk I.: Relationships between serum lipid, lipoprotein, triglyceride-rich lipoprotein, and high-density lipoprotein particle concentrations in post-renal transplant patients. JZUS-B, 11, 249, 2010.
13. Kimak E., Książek A., Solski J.: Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure. Clinical Chemistry and Laboratory Medicine, 44, 64, 2006.
14. Moren X., Deakin SP., Liu M.L. et al: HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress. J. Lipid Res., 49, 1246, 2008.
15. Ritz E., Wanner C.: Statin use prolongs patients survival after renal transplantation. J. Am. Soc. Nephrol., 19, 2035, 2009.
16. See V.Y., De Nofrio D., Goldberg L. et al.: Effect of atorvastatin on post cardiac transplant increase in low-density lipoprotein cholesterol reduces development of intima hyperplasia and progression of endothelial dysfunction. Am. J. Cardiol., 92, 11, 2003.
17. Takumoto T., Tanabe K., Ishida H. et al.: Impact of Fluvastatin on Hyperlipidemia after Renal Transplantation. Transplant. Proc., 36, 2141, 2004.
18. Tory R., Sachs-Barrable K., Goshko C.B. et al: Tacrolimus-Induced Elevation in Plasma Triglyceride Concentration after Administration to renal Transplant Patients in Partially Due to a Decrease in Lipoprotein Lipase Activity and Plasma Concentration. Transplantation, 1, 62, 2009.
19. Wiesbauer F., Heinze G., Mitterbauer C. et al: Statin use is associated with prolonged survival of renal transplant recipients. J. Am. Soc. Nephrol., 19, 2211, 2008.
Downloads
Published
Issue
Section
License
Copyright (c) 2010 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
